CMS, International Regulators’ Use Of Reference Pricing Causes Concern
This article was originally published in The Gray Sheet
Executive Summary
The initial launch price of a device into a foreign market may become fixed worldwide as CMS and foreign regulators increasingly rely on reference pricing, J&J/Cordis VP-Medical Affairs & Health Economics Brian Firth, MD/PhD, cautions
You may also be interested in...
J&J Building Competitive Advantages In CMS Skills And Drug-Device Combos
Cordis began working with the Centers for Medicare & Medicaid Services on reimbursement for Cypher as soon as the sirolimus stent entered clinical trials, Cordis World Wide Group Chairman Bob Croce told the Wharton Health Care Business Conference Feb. 20 in Philadelphia
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.